

Figure S1. Effect of MCP-1 on the proliferation of FLSs examined by 5-Bromo-2-deoxyuridine kit. MCP-1 at 100, 200 and 500 ng/ml significantly increased the proliferation of FLSs. Data are presented as the mean \pm SEM. *** P <0.001 vs. control group (0 ng/ml MCP-1). MCP-1, monocytes chemotactic protein 1; FLSs, fibroblast-like synoviocytes.




Figure S2. Effect of MCP-1 on the mRNA expression levels of VEGF and CD31. MCP-1 significantly increased the mRNA expression levels of (A) VEGF and (B) CD31 in FLSs, but not TNF- α . The present study observed that the increased expression levels of (C) VEGF and (D) CD31 induced by MCP-1 were also significantly reduced by PI3K and P38 inhibitors. Data are presented as the mean \pm SEM. **P<0.01, ***P<0.001 vs. control group. ###P<0.001 vs. MCP-1 group. MCP-1, monocytes chemo-tactic protein 1; VEGF, vascular endothelial growth factor; SB, SB203580; LY, LY294002; TNF- α , tumor necrosis factor- α .

